Get the Stockscreener App
37.98
5.94%
2.13
Tonix Pharmaceuticals Holding Corp stock is traded at $37.98, with a volume of 1.66M.
It is up +5.94% in the last 24 hours and down -15.13% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$35.85
Open:
$35.73
24h Volume:
1.66M
Relative Volume:
1.16
Market Cap:
$332.93M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-3.373
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-26.04%
1M Performance:
-15.13%
6M Performance:
+314.18%
1Y Performance:
+15.02%
1-Day Range:
$35.73
$39.45
1-Week Range:
$34.00
$53.55
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
37.98 | 351.25M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
SA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXP - Seeking Alpha
Tonix Pharmaceuticals Reports Q2 2025 Financial Results - MSN
Tonix Bets On Fibromyalgia Approval To Revive Growth Ambitions - Finimize
Tonix Pharmaceuticals' Tonmya: A First-in-Class Win with Long-Term Growth Potential - AInvest
Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade) - Seeking Alpha
Tonix receives FDA approval of Tonmya for treatment of fibromyalgia - Indian Pharma Post
Tonix Pharmaceutical’s Tonmya approved: first fibromyalgia drug in 15 years - Proactive Investors
First in 15 Years: Tonix Secures FDA Green Light for Tonmya in Fibromyalgia Treatment - geneonline.com
What moving averages say about Tonix Pharmaceuticals Holding Corp.July 2025 Update & Short-Term Swing Trade Alerts - Newser
Is it too late to sell Tonix Pharmaceuticals Holding Corp.2025 Macro Impact & Weekly Chart Analysis and Guides - Newser
Has Tonix Pharmaceuticals Holding Corp. found a price floorOptions Play & High Accuracy Swing Trade Signals - Newser
How to integrate Tonix Pharmaceuticals Holding Corp. into portfolio analysis toolsAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - Newser
Can momentum traders help lift Tonix Pharmaceuticals Holding Corp.2025 Market Overview & Long-Term Growth Stock Strategies - Newser
What MACD and RSI say about Tonix Pharmaceuticals Holding Corp.July 2025 PostEarnings & Technical Confirmation Alerts - Newser
Tonix Pharmaceuticals shares fall 21.29% intraday after FDA approval presentation. - AInvest
Tonix Pharmaceuticals Stock (TNXP) Opinions on Recent Price Surge and FDA Update - Quiver Quantitative
FDA Approval of Tonmya and the Paradox of Market Reaction for Tonix Pharmaceuticals (TNXP) - AInvest
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - Benzinga
Tonix Plunges 21.7%—What's Behind the FDA Approval Paradox? - AInvest
TNXP Plummets 22% on FDA Approval: What's Fueling the Volatility? - AInvest
Tonix drops 20% despite winning approval for fibromyalgia drug - Seeking Alpha
Tonix Pharmaceuticals' FDA Approval of Tonmya™ and Its Strategic Implications for Market Capture in Fibromyalgia - AInvest
Transcript : Tonix Pharmaceuticals Holding Corp.Special Call - MarketScreener
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’ - Stocktwits
Tonix Pharma Announces FDA Approval of Tonmya: A Milestone for Central Nervous System Disorder Treatment - AInvest
Tonix Pharma Announces FDA Approval of Tonmya - TipRanks
Tonix Pharmaceuticals shares rise 7.17% in premarket after FDA approval of Tonmya for fibromyalgia treatment. - AInvest
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, And Other Gainers & Losers - RTTNews
USFDA approves Tonix Pharma Tonmya for fibromyalgia in adults - Medical Dialogues
FDA approves Tonix’s Tonmya to treat fibromyalgia - Yahoo Finance
Tonix Pharmaceuticals TNXP Soars 12.58% on FDA Approval of Fibromyalgia Therapy - AInvest
Analyzing drawdowns of Tonix Pharmaceuticals Holding Corp. with statistical toolsJuly 2025 News Drivers & Accurate Entry and Exit Point Alerts - Newser
Can Tonix Pharmaceuticals Holding Corp. hit a new high this month2025 Performance Recap & Comprehensive Market Scan Insights - Newser
Analyzing recovery setups for Tonix Pharmaceuticals Holding Corp. investors2025 Retail Activity & Safe Entry Zone Identification - Newser
How to read the order book for Tonix Pharmaceuticals Holding Corp.July 2025 Earnings & Consistent Growth Equity Picks - Newser
Does Tonix Pharmaceuticals Holding Corp. fit your quant trading modelJuly 2025 Macro Moves & Weekly High Return Opportunities - Newser
Published on: 2025-08-17 21:45:37 - Newser
Key resistance and support levels for Tonix Pharmaceuticals Holding Corp.July 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Why Tonix Pharmaceuticals Holding Corp. stock is on top investor watchlistsWeekly Gains Report & AI Powered Market Trend Analysis - Newser
Healthcare Stocks Move in After-Market Session: DIH Holding, Tonix Pharmaceuticals, BioXcel Therapeutics Lead Gainers, Tivic Health Systems, CASI Pharmaceuticals Decline as Losers - AInvest
Tonix Pharmaceuticals Holding Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
FDA Approval of Tonmya™: A Catalyst for Tonix Pharmaceuticals' Growth and Investor Optimism - AInvest
FDA approves first new fibromyalgia treatment in over 15 years - The Pharma Letter
Tonix Secures Fibromyalgia ApprovalWhat Investors Should Know - Seeking Alpha
US FDA approves Tonix Pharma's drug to manage pain related to chronic condition - MSN
Tonix announces FDA approval of Tonmya for treatment of fibromyalgia - MSN
Tonix Pharmaceuticals' Tonmya: A Game-Changer in Fibromyalgia Treatment and Its Long-Term Investment Potential - AInvest
Published on: 2025-08-16 03:29:29 - Newser
Tonix Pharma's Tonmya: A Game-Changer in Fibromyalgia Treatment and a High-Risk, High-Reward Investment Opportunity - AInvest
Identifying reversal signals in Tonix Pharmaceuticals Holding Corp.Earnings Risk Report & Fast Gain Swing Alerts - Newser
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):